Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Microsoft — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Microsoft trades at $501.12 (market cap $3.74T). The key difference: Microsoft is far larger — about 126.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Microsoft pays a 0.72% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MSFT | |
|---|---|---|
Market Cap | $29.60B | $3.74T |
Sector | Health | Technology |
52-Week High | $491.22 | $542.07 |
52-Week Low | $205.48 | $352.83 |
Enterprise Value | $27.56B | $3.72T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Microsoft (MSFT) trades at $506.06, up 1.21% with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with $281.72B revenue, 40.31% net margin, and consistent earnings beats. Recent news highlights Microsoft's AI leadership and Azure growth potential, though concerns about capital expenditures persist. The stock trades near pivot point resistance at $507 with strong support at $500.
Outlook remains positive with 80% analyst buy ratings and $552.73 consensus target offering 9% upside. Key opportunities include AI integration and cloud growth, while risks involve competitive pressures and execution on large capital investments. The combination of strong fundamentals and technical momentum supports a constructive view for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
